Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 31;4(6):fcac269. doi: 10.1093/braincomms/fcac269

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

CHOP-INTEND, HINE-2 and HFMSE scores of individual patients during treatment with nusinersen. Motor function trajectories reflected by CHOP-INTEND, HINE-2 and HFMSE scores in symptomatic children with SMA types 1b-3a. Each individual (coloured) line represents one patient. Baseline assessment is indicated by asterisks, while follow-up assessments are indicated by squares. Effects of nusinersen treatment were associated with disease duration at treatment initiation and age at the start of treatment (likelihood ratio test: P < 0.001). (A) CHOP-INTEND scores in patients with SMA type 1, including types 1b and 1c. (B) HINE-2 scores in patients with SMA type 1, including types 1b and 1c. (C) HMFSE scores in patients with SMA type 2, including types 2a and 2b. (D) HFMSE scores in patients with SMA type 3a.